acid (GEMSA) selectively labels the carboxypeptidase B-like enzyme enkephalin convertase (EC) in rat brain tissue sections. We have used autoradiography with 3H-GEMSA to map membrane-bound EC in the rat forebrain and, in conjunction with lesioning techniques, to localize EC to specific neuronal pathways. The highest levels of EC are in the median eminence. High levels of EC also occur in the hypothalamic magnocellular nuclei, in several nuclei of the amygdala, the lateral septum, and the bed nuclei of the stria terminalis. Knife-cut lesions of the stria terminalis increase EC posterior to the lesion in the stria and deplete EC from the stria adjacent to the bed nucleus, suggesting that EC, like enkephalins, is axonally transported within the stria terminalii. Ibotenic acid lesions of the caudate nucleus destroy binding in the substantia niga pars reticulata ipsilateral to the lesion, suggesting that nigral EC is associated with axons originating in the caudate nucleus. We have also mapped EC in detail in the hippocampus. EC levels are highest near pyramidal cells of CA 3-4 and the dentate gyrus granule cells. Quinolinic acid lesions destroy both the granule and pyramidal cells and destroy all of the 3H-GEMSA labeling except for a small amount in the molecular layer of the dentate gyrus. Selective destruction of CA 3-4 pyramidal cells with kainic acid eliminates EC in the pyramidal cell region. Destruction of granule cells of the dentate gyrus with colchicine depletes binding in the dentate gyrus without any change in the area surrounding field CA 3-4. High levels of 3H-GEMSA binding are present in the hippocampus at least 3 d before birth. These observations suggest that in the hippocampus the majority of EC is associated with pyramidal cells, which have not been shown to contain enkephalins. 'H-GEMSA autoradiography of the trigeminal ganglion localizes EC to the sensory neurons and not to white matter tracts there. These studies demonstrate that while EC is contained in enkephalinergic pathways, it is also present in some neurons that do not contain enkephalins.
peptidase B-like enzyme are capable of releasing the active peptide from the precursor. The sequences of 2 putative precursors of the enkephalins, designated proenkephalin A and proenkephalin B/prodynorphin, have a similar structure, in which multiple copies of Leu-or Met-enkephalin are flanked by 2 basic amino acids (Comb et al., 1982; Gulber et al., 1982; Kakidani et al., 1982; Noda et al., 1982) . Proenkephalin A contains 4 copies of Met-enkephalin and 1 of Leu-enkephalin flanked by dibasic amino acids. Proenkephalin B/prodynorphin contains 3 copies of Leu-enkephalin, each of which is contained within one of the longer opioid peptides dynorphin, the neoendorphins, or rimorphin. Recent evidence has suggested that these precursors are processed to different products in different areas of the body. While proenkephalin A is processed to the enkephalins in the brain, in the adrenal it produces higher molecular weight peptides containing enkephalin (Boarder et al., 1982; Kimura et al., 1980; Lewis et al., 1979) . Levels of the various proenkephalin B/prodynorphin-derived peptides vary regionally within the brain, suggesting that processing of proenkephalin B displays similar variations (Seizinger et al., 1984; Zamir et al., 1984a) . Thus, the activity of processing enzymes in different tissues or brain regions should affect which opioid peptides are formed from a given precursor in a specific location.
Such tissue-specific and regional-processing differences highlight the importance of identifying the enzymes that process enkephalin precursors. In proenkephalin processing, the sequential action of a trypsin-like enzyme, and a carboxypeptidase B-like enzyme can release mature peptide from its position flanked by dibasic sequences. The carboxypeptidase B-like enzyme directly forms enkephalins by releasing basic amino acids from the carboxyl terminus of the products of a trypsin-like cleavage. We have previously described a novel carboxypeptidase B-like enzyme termed enkephalin convertase (EC) (EC 3.14.17.10) that may act physiologically in the processing of enkephalins. It has an optimum pH of 5.5, is present in both membrane and soluble forms, and has been colocalized with enkephalins in adrenal chromalhn granules Snyder, 1982,1983; Supattapone et al., 1984) . EC is inhibited potently and selectively by guanidinoethylmercaptosuccinic acid (GEM-SA) with a X; of about 5 nM . GEMSA has a Kc for other carboxypeptidase B-like enzymes of greater than 1 PM so that at low concentrations GEMSA interacts selectively with EC. 3H-GEMSA binds only to EC under assay conditions we described previously in both homogenates and in tissue sections (Lynch et al., 1984; Strittmatter et al., 1984b) .
We used the specificity of 3H-GEMSA for EC to localize the membrane bound form of EC in the brain by in vitro autoradiography. The distribution of EC in a variety of brain regions generally parallels that ofenkephalins (Lynch et al., 1984) . However, our previous study did not assess whether EC is found in the same neuronal pathways as enkephalins. Enkephalins have B, Matching half-section incubated with 1.5 nM 'H-GEMSA and 10 &M unlabeled GEMSA. White areas indicate areas of high binding. Binding is high in the supraoptic Q and paraventricular (P) nuclei of the hypothalamus, the primary olfactory cortex (PC), the nucleus of the lateral olfactory tract (L), the central nucleus of the amygdala (c). and the CA 3 region of the hippocampus (3). Binding is moderate in the CA 1 field of the hippocampus (I), the thalamus (Z'), and the caudate-putamen (0). Binding is low in white matter areas such as the internal capsule (ZC) and the fomix (arrow). Panels C and D demonstrate high levels of binding in the supraoptic nucleus, with C showing autoradiographic grains and D tissue staining with toluidine blue.
been localized to certain discrete pathways in the brain, including the stria terminalis (Uhl et al., 1978) and a striatonigral pathway (Correa et al., 198 1; Cue110 and Paxinos, 1978) . Proenkephalin B-derived peptides are found within the mossy fiber pathway in the hippocampus (McGinty et al., 1983) . In the present study we have extended our previous findings by using lesioning techniques to localize EC to specific neuronal pathways. In addition, we have mapped the distribution of EC in detail within the rat forebrain and especially within the hippocampus.
Materials and Methods

Materials
3H-GEMSA was obtained from New England Nuclear (Boston), unlabeled GEMSA from Calbiochem (La Jolla, CA), and colchicine and kainic acid from Sigma (St. Louis).
3H-GEMSA autoradiography
The method for 'H-GEMSA autoradiography has been described previously (Lynch et al., 1984) . For routine experiments, 8 pm cryostat sections were incubated for 5 min at 4°C in 50 mM sodium acetate, pH 5.5, followed by incubation for 30 mm in the same buffer with labeled GEMSA and any inhibitors. The sections were washed twice for 1 mitt in the same bulk and dried under a stream of cool air. Nonspecik binding was determined by incubation in the presence of 10 CM unlabeled GEMSA. The 3H-GEMSA concentration was 0.75 or 1.5 nM for routine experiments. Sections were exposed to LKB ultrafllm for approximately 16 d or to emulsion-coated coverslips for about 3 weeks. Autoradiograms were quantitated using a computer-as&ted imaaeanalysis system (Kuharet al., 1984) and converted to picomoles %I-GEMSA bound per milliaram nrotein usina standards (Dnnerstall et al., 1982) . Following aut&adiography, sect&s were stained with toluidine blue.
Cholinesterase staining was performed by the method of Ralis et al. (1973) .
Animals
Male Sprague-Dawley rats, 175-200 gm, were prepared for automdiography and pet-l&d with phosphate-bntkred sucrose and no lixative as described previously (Young and Kuhar, 1979) . For studies with neonatal rats, the rats were not perfused, instead, the rats were decapitated and the brain removed, mounted in brain paste, and frozen rapidly on dry ice.
Lesioning techniques
Knife-cut lesions of the stria terminalis were conducted as described previously by Uhl et al. (1978) . In this method, a knife was stereotaxically lowered through the skull so as to sever the stria terminalis horizontally and unilaterally.
Lesions of both the pyramidal and granule cells of the hippocampal formation were conducted by intrahippocampal injection of 200 nmol of quinolinic acid (Schwarz et al., 1983) . Animals were sacrificed 4 d later, and tissue staining continned the destruction of both the hippocampal pyramidal cells and the dentate gyms gramde cells. CA 3-4 pymmidalcellswerelesionedbyamodi6ciltionofthemethodofMcGinty et al. (1983) in which 1 @ of kainic acid was injected intrahippocampally. Animals were sacrificed 3-4 d later. Granule cells were lesioned by the method of McGinty et al. (1983) , in which 3 pg of colchicine was injected into the dorsal and ventral hila of the hippocampus. Animals were sacriked 8 d later. In all of these lesions, the opposite side was injected with saline to serve as a control for the lesioned side. Lesions of the striatonigral pathway with ibotenic acid were performed as described previously by St&matter et al. (1984a) , and animals were sacrificed after 14 d.
Results
The specificity of 3H-GEMSA for EC has been demonstrated previously in tissue sections (Lynch et al., 1984) . Its binding to tissue sections has a pharmacological profile that matches that of EC catalytic activity. Binding to tissue sections is saturable with a KD of about 5 nM, which is consistent with the potent inhibition of EC activity by GEMSA. In conjunction with the specific interaction of GEMSA with EC enzymatically and in homogenate binding, these findings indicate that 3H-GEMSA labels only EC in tissue sections. Nonspecific binding (Fig. 1B) is negligible, so that all grains observed represent specific binding to EC.
Selected regions with high levels of 3H-GEMSA binding have been examined at higher resolution than our previous study Figure 3 . Enkephalin convertase in lesions of the stria terminalis. The stria terminalis was unilaterally transected on the left as described under Materials and Methods. A, 'H-GEMSA autoradiogram of a section behind the cut with an accumulation of EC in the stria terminalis (arrow) ipsilaterally behind the transection; no effect on EC is seen in the hippocampus (H) or cerebral cortex. B, Section in front of the transection demonstrating a depletion of EC within the stria terminalis (arrow) ipsilateral to the lesion (left) and adjacent to the bed nucleus of the stria terminalis (B) but not within the internal capsule (IQ the fomix Q, or anterior commissure (AC'). The reproducibility of the labeling in this portion of the stria is shown in a similar section from an unlesioned animal (c). Lynch et al. Vol. 6, No. 6, Jun. 1966 c .
( Fig. l) , and the distribution of membrane EC has been determined in detail in the rat forebrain (Table 1) . EC levels are highest in the median eminence (Fig. 2) , where EC is mainly found in the outer zone. In the diencephalon, EC levels are greater in the hypothalamus than in the thalamus, with particularly high levels in the magnocellular nuclei. Several of the amygdaloid nuclei have high levels of EC, especially the central and posterior cortical nuclei. EC levels are high in limbic system areas, including the lateral septum, the bed nucleus of the stria terminalis, and the hippocampus. EC is distributed heterogeneously in the cerebral cortex, with the primary olfactory and entorhinal cortex having higher levels than the parietal or frontal cortex. Using lesion studies in conjunction with autoradiography, we have obtained evidence that EC occurs in specific pathways. After transection of the stria terminalis, EC levels are increased posterior to the lesion in the stria and depleted from the stria adjacent to the bed nucleus (Fig. 3) . The unilateral depletion in Figure 4 . Enkephalin convertase in the striatonigral pathway. The substantia nigra (A) or the caudate-putamen (B) were lesioned unilaterally on the right side with ibotenic acid as described under Materials and Methods. Nigral lesions have no effect on the EC, demonstrated by "H-GEMSA autoradiography in the substantia nigra pars reticulata (arrows in A), while caudate lesions deplete EC within the pars reticulata of the nigra ipsilateral to the lesion (right, arrows in B). The periaqueductal gray (G) and medial leminiscus (M) are not affected by the lesions.
3H-GEMSA binding in the rostral portion of the stria is incom-EC levels are low in the caudate nucleus and moderate in the plete (Fig. 3B) . EC levels are not affected in the cerebral cortex globus pallidus and substantia nigra pars reticula&t. Lesioning disrupted on the lesioned side, demonstrating the specificity of the caudate nucleus with ibotenic acid destroys binding in the this effect for the stria terminalis.
substantia nigra pars reticula&t ipsilateral to the lesion but not Figure 5 . Enkephalin convertase in the hippocampal formation. A, Section through the hippocampus incubated with 1.5 nM "H-GEMSA and 10 PM unlabeled GEMSA. B, Identical section incubated in 1.5 nM "H-GEMSA alone. Specific labeling is found in both the dentate gyrus (G) and the hippocampus, particularly CA 3 (3). Labeling is also found in the entorhinal cortex Q and the amygdalohippocampal area (AH), with lower levels in the habenula (H), thalamus (I), and external capsule (C). At higher power (C, tissue staining; D, autoradiographic grains), the grains in the dentate gyms are found mainly in the inner part of the molecular layer (M) and in lower levels directly over the granule cells (arrows). High labeling is also found over the pyramidal cells (P), with lower levels in the stratum radiatum (R) and CA 1 (1) area and in the adjacent part of the thalamus (t). In the hippocampus (E, tissue staining; F, autoradiography grains), the grains are directly over the pyramidal cells of CA 3 (3) and CA 4 (4), with lower levels over the dendritic fields of the pyramidal cells. Lower levels of binding are seen in the fomix Q, the adjacent thalamus (I), and the external capsule (c).
contralateral to it (Fig. 4) . This suggests that nigral EC is associated with axons originating in the caudate nucleus. Injection of ibotenic acid in the substantia nigra does not affect 3H-GEM-SA binding there (Fig. 4) , confirming that nigral EC is associated with extrinsic cell bodies and not nigral neurons.
Distribution of EC in the hippocampal formation Both homogenate binding and autoradiography reveal the presence of high levels of 3H-GEMSA binding in the hippocampus. EC levels in the hippocampus (Fig. Figure 6 . Enkephalin convertase in the intrinsic hippocampal neurons. The hippocampus was lesioned unilaterally on the right side with quinolinic acid as described in Materials and Methods. The lesion destroyed both the granule cells and the pyramidal cells, as shown by toluidine blue staining (A) and abolished the 3H-GEMSA binding (B) except for a small amount in the molecular layer of the dentate gyms. Cholinesterase staining (C') showed that the hippocampal afferents were left intact. 5) are highest around the pyramidal cells, especially CA 3-4, and the granule cells of the dentate gyrus. Lower levels are found in both the stratum oriens and the stratum radiatum of the hippocampus. At higher magnification, 3H-GEMSA-associated grains appear directly over the pyramidal cells in the hippocampus and over the granule cells and the innermost portion of the molecular layer in the dentate gyrus. One interpretation of these data is that EC here is largely in the mossy fiber pathway, which projects from the dentate gyrus to the stratum lucidum around CA 3-4. Lesioning studies demonstrate a more complex distribution of EC here. Quinolinic acid lesions destroy both the granule and pyramidal cells by histologic criteria, while cholinesterase staining confirms that hippocampal afferents are left intact by this lesion (Fig. 6) . With the exception of a thin layer of binding in the inner portion of the molecular layer of the dentate gyrus, 3H-GEMSA-associated grains are eliminated. Thus, except for a few afferents terminating in the inner portion of the molecular layer, the majority of binding is associated with intrinsic hippocampal neurons and not with hippocampal afferents or glia in the hippocampus.
A kainic acid lesion that selectively destroys the pyramidal cells of CA 3-4 is shown in Figure 7 . Cholinesterase staining confirms that hippocampal afferents to CA 3-4 are left intact (Fig. 7C) . Binding in the dentate gyrus and around CA l-2 is unaffected by this lesion, while the binding around CA 3-4 is depleted. Thus, EC here is localized to the pyramidal cells or possibly to small interneurons in the pyramidal cell area and not to the mossy fibers originating in the dentate gyms. This conclusion is supported by lesions of the granule cells with colchicine (Fig. 7, D and E) . This lesion removes some of the binding in the dentate gyrus but does not affect binding in the area around CA 3-4. The binding remaining in the dentate gyms is likely associated with the same afferents demonstrated by the quinolinic acid lesion. The binding that is destroyed in the dentate gyrus is probably associated with the granule cells. This lesion clearly demonstrates that the binding around CA 3-4 of the hippocampus is not associated with the granule cell mossy fiber projection, as the binding is not destroyed by this lesion. Accordingly, the pyramidal cells of CA 3-4, the afferents to the inner portion of the molecular layer, and probably the dentate gyrus granule cells contain EC.
Studies of EC development in the hippocampus agree with these localizations. The granule cells develop late in the rat, and most do not undergo their final division until after birth (Altman, 1966) . However, high levels of 3H-GEMSA binding are present in the hippocampus at least 3 d before birth (Fig. 8) . There is increased binding around CA 3-4 but only a small amount of binding in the area that will become the dentate gyms. Over the next 9 d of development, the binding in the dentate gyrus reaches adult levels and is distributed in the same pattern as in the adult. Since the mossy fiber projection from the dentate gyrus to the stratum lucidum around CA 3-4 develops in the postnatal period (Amaral and Dent, 198 l) , the high levels around CA 3-4 before birth cannot be associated with this pathway. The development of EC in the dentate gyrus around postnatal days 3-5 is likely associated with the granule cells or their afferents. Thus, both the developmental and lesioning studies suggest that EC in the hippocampal formation is associated with the hippocampal pyramidal cells, as well as with the granule cells or their afferents.
Localization in the trigeminal ganglion
The large size of the hippocampal pyramidal cells and the granule cells makes them amenable for studying EC localization. The cells of the trigeminal ganglia are also easily accessible and so have been examined by autoradiography with 3H-GEMSA. In the trigeminal ganglion, 3H-GEMSA binding is localized to sensory neurons and not to the white matter tracts passing through the ganglion (Fig. 9) . The grains are associated with a majority of the ganglion cells, although the exact proportion cannot be quantitated by autoradiography.
Discussion
The present study indicates an association of EC with enkephalin-containing brain regions but not only with those regions. The general distribution of EC in the rat forebrain resembles that of enkephalins, with the highest levels in the hypothalamus, the amygdala, the lateral septum, and the bed nucleus of the stria terminalis (Petrusz et al., 1985) . In particular, EC localization corresponds closely to enkephalins and proenkephalin B-derived peptides in the central nucleus of the amygdala and the magnocellular nuclei of the hypothalamus. The heterogeneous distribution of EC in the cerebral cortex, with higher levels in the primary olfactory and entorhinal areas, is also consistent with a role in proenkephalin processing. However, many of these regions contain other peptide neurotransmitters, including neurotensin and substance P (Ljundahl et al., 1978; Uhl et al., 1977) .
The studies conducted here likely localize only the membranebound form of EC. Using the tissue preparation conditions described here, previous studies have shown that soluble angiotensin-converting enzyme and benzodiazepine receptors (Lo et al., 1983) are not detected by autoradiography. In the anterior pituitary, the levels of EC detected by autoradiography match the distribution of membranebound but not soluble EC (Strittmatter et al., 1985) . Thus, 'H-GEMSA autoradiography localizes only one form of EC. We attempted to retain the soluble form in the tissue sections by fixation with increasing concentrations of paraformaldehyde prior to incubation with 3H-GEMSA. However, this resulted only in the inhibition of binding activity.
The lesion studies of the stria terminalis demonstrate the presence of EC in one enkephalinergic pathway. The stria terminalis projects from the central nucleus of the amygdala to the bed nucleus of the stria terminalis and has previously been shown to contain enkephalins and neurotensin (Uhl and Snyder, 1979; Uhl et al., 1977 Uhl et al., , 1978 . The present study shows that, like enkephalins and neurotensin, EC is axonally transported in the stria terminalis, accumulating posterior to transections of the stria and diminishing anterior to such lesions. Such lesions do not fully deplete enkephalins or EC from the bed nucleus of the stria terminalis, probably because both EC and enkephalins occur in interneurons in the bed nucleus (Uhl et al., 1978) .
In a few other regions of the forebrain the distribution of EC does not parallel that of enkephalins. The levels of EC in the caudate-putamen and globus pallidus are low compared to the amount of enkephalins. Enkephalins here occur within striatopallidal and, with substance P, in a striatonigral pathway (Correa et al., 198 1; Cue110 and Paxinos, 1978; Jessell, 1982) . Despite the low levels of EC in these regions, the striatonigral lesion studies indicate that EC is present in a striatonigral pathway. The low levels of EC in the caudate may reflect reduced peptide processing in this pathway. In the caudate, globus pallidus, and substantia nigra, levels of cY-neoendorphin are approximately 5 x greater than /3-neoendorphin (Seizinger et al., 1984; Zamir et al., 1984b, c) . Since the production of @-neoendorphin from a-neoendorphin can be catalyzed by a carboxypeptidase B-like processing enzyme, the lower levels of EC observed here may explain the alteration in the ratios of the neoendorphins.
The distribution of EC contrasts with that of enkephalins in the hippocampal formation. The inputs and projections of the hippocampal formation have been relatively well characterized (Walaas, 1983) . The dentate gyrus receives input onto its molecular layer from the entorhinal cortex and from the septum, and the granule cells of the dentate gyrus project through the mossy fibers to the pyramidal cells of regions CA 3-4 of the hippocampus. The CA 3 pyramidal cells project to the CA 1 pyramidal cells, the septum, the subiculum, and the entorhinal cortex. Enkephalin levels are relatively low in the hippocampal formation and have been localized immunocytochemically to the perforant pathway from the entorhinal cortex (Gall et al., 198 I) , while proenkephalin B-derived peptides are found in the mossy fiber pathway within the hippocampal formation (Chavkin et al., 1985; McGinty et al., 1983) . However, our lesion studies suggest that EC in this region has a different distribution. The majority of hippocampal EC is present in the hippocampal pyramidal cells and in afferents to the inner portion of the molecular layer of the dentate gyrus. Lesser amounts of EC may colocalize with EC in dentate gyrus granule cells.
The developmental course of EC in the hippocampus is consistent with the localization of EC to pyramidal cells. EC is found in the hippocampus at embryonic day 20, while the mossy fiber Vol. 6, No. 6, Jun. 1986 pathway from the dentate gyrus to the hippocampus develops after birth (Amaral and Dent, 198 1) . This result supports the conclusion that EC develops first in the pyramidal cells of the hippocampus.
EC levels in the dentate gyrus are low before birth in the rat but by day 5 after birth resemble the adult distribution. This is consistent with the development of EC in either the granule cells, many of which undergo their final division after birth, or in the afferents to the granule cells. The afferents to the granule cells develop mainly after postnatal day 4 (Crain et al., 1973) so that the developmental course of EC agrees with the evidence from lesion studies that EC is found in granule cell afferents. Enkephalin-like immunoreactivity develops in the hippocampus after birth, so that the development of EC here precedes that of enkephalins (Gall et al., 1984) . Interestingly, the hippocampal pyramidal cells are not thought to contain enkephalin; thus, EC in these cells presumably acts on substrates other than enkephalin precursors. However, as yet no peptide neurotransmitters have been found within the pyramidal cells (Walaas, 1983) .
EC may also process peptides other than enkephalin precursors in the trigeminal ganglion. 3H-GEMSA binding is discretely localized to the sensory cells with low levels in the white matter. The autoradiographic studies do not differentially localize EC to the sensory versus the satellite cells. However, given the strong association of EC with gray matter regions in the brain, the enzyme is likely to be found in sensory cells. The sensory cells do contain VIP, substance P, calcitonin gene-related peptide, and, in some cases, may contain an excitatory amino acid neurotransmitter (Hunt, 1983) . However, there is no evidence that they contain enkephalins. Thus, EC here presumably is involved in the metabolism of other peptides.
